# Aditxt Inc. (ADTX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $691.068  
**Price:** $0.02 (-36.21%)

> Aditxt Inc. is a life sciences company focused on developing and commercializing biotechnologies that monitor and modulate the immune system. Its core technologies include AditxtScore™, an immune monitoring platform that provides personalized profiles to help individuals understand, manage, and track their immune responses against attacks on or by the immune system, and Apoptotic DNA Immunotherapy™ (ADI™), a nucleic acid-based approach that retrains the immune system to induce tolerance for applications in organ transplantation, autoimmune diseases like psoriasis, type 1 diabetes, multiple sclerosis, and allergies. The company advances products such as ADI-100 for skin grafting and other immune-related conditions through subsidiaries like Adimune, which handles DNA-based therapeutics, and Pearsanta, specializing in precision diagnostics including Mitomic® and Adductomics testing platforms for women's health and early disease detection. Aditxt Inc. operates in the health technology and biotechnology sectors, emphasizing immune health, precision health, population health, neurologic health, and women's health. Founded in 2017 and headquartered in Mountain View, California, it serves as an innovation platform bridging immune reprogramming and monitoring to address unmet needs in immunotherapy and diagnostics.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3,195 | $268 | -$20M | -$43M | — |
| 2024 | $133,985 | -$493,489 | -$28M | -$40M | — |
| 2023 | $645,176 | -$111,660 | -$26M | -$33M | — |
| 2022 | $933,715 | $166,936 | -$25M | -$28M | — |
| 2021 | $105,034 | $27,055 | -$42M | -$46M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $17M | $13M | $6M | — | — |
| 2024 | $32M | $24M | $2M | $833,031 | — |
| 2023 | $45M | $29M | $16M | $97,102 | — |
| 2022 | $11M | $6M | $5M | $3M | — |
| 2021 | $17M | $6M | $10M | $8M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$26M | $13,743 | -$26M |
| 2024 | -$17M | — | — |
| 2023 | -$19M | $14,407 | -$19M |
| 2022 | -$22M | $367,079 | -$23M |
| 2021 | -$22M | — | — |
| 2020 | -$7M | — | — |
| 2019 | -$464,352 | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/ADTX)